Butaclamol

Last updated

Butaclamol
Butaclamol.svg
Clinical data
ATC code
  • none
Identifiers
  • (3S,4aS,13bS)-3-(2-Methyl-2-propanyl)-2,3,4,4a,8,9,13b,14-octahydro-1H-benzo[6,7]cyclohepta[1,2,3-de]pyrido[2,1-a]isoquinolin-3-ol
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
ChEBI
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
Formula C25H31NO
Molar mass 361.529 g·mol−1
3D model (JSmol)
  • CC(C)(C)C1(CCN2CC3C4=CC=CC=C4CCC5=C3C(=CC=C5)C2C1)O

Butaclamol (AY-23,028) is a type of antipsychotic which was never marketed. [1] Sold as the hydrochloride salt for use in research, the compound acts as a dopamine receptor antagonist. [2]

Contents

Synthesis: [3] Review: [4] Book chapter: [5]

Chemistry

pKa = 7.15 (uncorrected for ionic strength) [6]

See also

References

  1. Buckingham J (1985). Dictionary of organic compounds - Google Books. CRC Press. ISBN   978-0-412-54090-5.
  2. Hall DA, Strange PG (June 1997). "Evidence that antipsychotic drugs are inverse agonists at D2 dopamine receptors". British Journal of Pharmacology. 121 (4): 731–6. doi:10.1038/sj.bjp.0701196. PMC   1564749 . PMID   9208141.
  3. Bruderlein, F. T., Humber, L. G., Voith, K. (February 1975). "Neuroleptic agents of the benzocycloheptapyridoisoquinoline series. 1. Syntheses and stereochemical and structural requirements for activity of butaclamol and related compounds". Journal of Medicinal Chemistry. 18 (2): 185–188. doi:10.1021/jm00236a016. PMID   1168258.
  4. Castañer, J., Chatterjee, S. S. (1976). "Butaclamol". Drugs of the Future. 1 (4): 171. doi:10.1358/dof.1976.001.04.64761.
  5. Chronicles of Drug Discovery, Volume 1, Edited by Jasjit S. Bindra and Daniel Lednicer, page 61, (L. G. Humber).
  6. Chrzanowski FA, McGrogan BA, Maryanoff BE (March 1985). "The pKa of butaclamol and the mode of butaclamol binding to central dopamine receptors". Journal of Medicinal Chemistry. 28 (3): 399–400. doi:10.1021/jm00381a022. PMID   2579238.